Business Description
Labo Euromedis
ISIN : FR0000075343
Compare
Compare
Traded in other countries / regions
ALEMG.France61R.Germany0I0L.UK IPO Date
2000-03-27Description
Labo Euromedis is engaged in medical devices. It is engaged in the design, manufacture, rental and export of medical and surgical equipment and products.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.88 | |||||
| Equity-to-Asset | 0.49 | |||||
| Debt-to-Equity | 0.44 | |||||
| Debt-to-EBITDA | 0.42 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 1.67 | |||||
| Beneish M-Score | -3.49 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -16.3 | |||||
| 3-Year EBITDA Growth Rate | -29 | |||||
| 3-Year EPS without NRI Growth Rate | -19.4 | |||||
| 3-Year FCF Growth Rate | 9.5 | |||||
| 3-Year Book Growth Rate | 29.9 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 41.58 | |||||
| 9-Day RSI | 50.52 | |||||
| 14-Day RSI | 54.11 | |||||
| 6-1 Month Momentum % | -2.39 | |||||
| 12-1 Month Momentum % | -23.12 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.41 | |||||
| Quick Ratio | 3.34 | |||||
| Cash Ratio | 2.12 | |||||
| Days Inventory | 225.54 | |||||
| Days Sales Outstanding | 97.91 | |||||
| Days Payable | 161.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.4 | |||||
| Shareholder Yield % | 19 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 48.7 | |||||
| Operating Margin % | -16.85 | |||||
| Net Margin % | 38.56 | |||||
| FCF Margin % | -15.21 | |||||
| ROE % | 45.57 | |||||
| ROA % | 24.46 | |||||
| ROIC % | -25.99 | |||||
| ROC (Joel Greenblatt) % | 144.12 | |||||
| ROCE % | 49.81 | |||||
| Years of Profitability over Past 10-Year | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 1.11 | |||||
| PE Ratio without NRI | 1.11 | |||||
| Shiller PE Ratio | 6.76 | |||||
| PS Ratio | 0.44 | |||||
| PB Ratio | 0.65 | |||||
| Price-to-Tangible-Book | 0.65 | |||||
| EV-to-EBIT | 0.26 | |||||
| EV-to-EBITDA | 0.25 | |||||
| EV-to-Revenue | 0.17 | |||||
| EV-to-FCF | -1.2 | |||||
| Price-to-Projected-FCF | 0.29 | |||||
| Price-to-Median-PS-Value | 1.23 | |||||
| Price-to-Graham-Number | 0.18 | |||||
| Price-to-Net-Current-Asset-Value | 0.94 | |||||
| Earnings Yield (Greenblatt) % | 377.93 | |||||
| FCF Yield % | -35.19 | |||||
| Forward Rate of Return (Yacktman) % | -4.32 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers